BRAF and melanoma: Since Gal‐1 favors the expansion of these cell populations (Juszczynski et al., 2007; Rubinstein et al., 2004), increased infiltrates of these cells in BRAF inhibitor‐treated melanomas might be driven, at least partially, by Gal‐1 overexpression.